| Recruiting | A Study to Evaluate the Safety, Tolerability, and Efficacy of BMS-986523 Alone and in Combination With Anti-Ca NCT07223047 | Bristol-Myers Squibb | Phase 1 / Phase 2 |
| Recruiting | A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), and Preliminary Efficacy of BC2027 in Pat NCT07368478 | Biocity Biopharmaceutics Co., Ltd. | Phase 1 |
| Recruiting | Phase I Study of the Safety, Tolerability, and Efficacy of an Engineered Mitochondrial Vaccine in Advanced Sol NCT06927297 | West China Hospital | Phase 1 |
| Active Not Recruiting | Phase I/Ib Trial of TIraGolumab, AtEzolizumab, and RadScopal Radiation in Patients With Advanced Solid Maligna NCT06760481 | M.D. Anderson Cancer Center | Phase 1 |
| Active Not Recruiting | Modular Clinical Pharmacology Study to Evaluate the Drug-drug Interaction Potential and Relative Bioavailabili NCT06899061 | AstraZeneca | Phase 1 |
| Suspended | A Phase I Study of BR115 for Injection Alone in Subjects With Advanced Solid Malignancies NCT06388902 | BioRay Pharmaceutical Co., Ltd. | Phase 1 |
| Recruiting | Safety and Tolerability Study of GIM-122 in Subjects With Advanced Solid Malignancies NCT06028074 | Georgiamune Inc | Phase 1 / Phase 2 |
| Completed | Drug-drug Interaction Study With AZD5305 and Itraconazole in Patients With Advanced Solid Malignancies NCT05573724 | AstraZeneca | Phase 1 |
| Recruiting | Study of AZD9574 as Monotherapy and in Combination With Anti-cancer Agents in Participants With Advanced Solid NCT05417594 | AstraZeneca | Phase 1 / Phase 2 |
| Completed | An Open-Label Phase 1 Study of Ceralasertib in Japanese Patients With Advanced Solid Malignancies NCT05469919 | AstraZeneca | Phase 1 |
| Recruiting | A Phase I/II Study to Evaluate the Safety, Pharmacokinetics and Efficacy of PRJ1-3024 in Subjects with Advance NCT05315167 | Zhuhai Yufan Biotechnologies Co., Ltd | Phase 1 / Phase 2 |
| Active Not Recruiting | A Phase I Study, Evaluating the Safety, Pharmacokinetics and Efficacy of PRJ1-3024 in Subjects With Advanced S NCT05159700 | Zhuhai Yufan Biotechnologies Co., Ltd | Phase 1 |
| Unknown | A Phase I Open-label Study for Subjects With Advanced Malignancies NCT04136834 | Athenex, Inc. | Phase 1 |
| Unknown | Evaluate Safety, Tolerability, PK, Preliminary Clinical Activity of OB318 in Patients With Advanced Solid Mali NCT02347228 | Oneness Biotech Co., Ltd. | Phase 1 |
| Active Not Recruiting | Safety and Efficacy Study of CFI-402411 in Subjects With Advanced Solid Malignancies NCT04521413 | Treadwell Therapeutics, Inc | Phase 1 / Phase 2 |
| Completed | A Study to Evaluate the Safety, Tolerability and How YH002 Enters, Moves Through and Exits the Body in Subject NCT04353102 | Eucure (Beijing) Biopharma Co., Ltd | Phase 1 |
| Completed | A Phase I Study of AZD4635 in Japanese Patients With Advanced Solid Malignancies NCT03980821 | AstraZeneca | Phase 1 |
| Completed | A Phase I Study of MEDI9447 (Oleclumab) in Japanese Patients NCT03736473 | AstraZeneca | Phase 1 |
| Completed | Study of AZD9150 and MEDI4736 (Durvalumab) in Japanese Adult Patients With Advanced Solid Malignancies NCT03394144 | AstraZeneca | Phase 1 |
| Completed | Modular Study to Evaluate CT7001 Alone in Cancer Patients With Advanced Malignancies NCT03363893 | Carrick Therapeutics Limited | Phase 1 / Phase 2 |
| Completed | An Open-Label, Multi-Centre, Study to Assess the Safety of Fixed-Dose Durvalumab + Tremelimumab Combination Th NCT03084471 | AstraZeneca | Phase 3 |
| Completed | A Phase 1 Clinical Study of AZD4635 in Patients With Advanced Solid Malignancies NCT02740985 | AstraZeneca | Phase 1 |
| Completed | Dose-Seeking Study of MPT0E028 in Subjects With Advanced Solid Malignancies Without Standard Treatment NCT02350868 | Taipei Medical University | Phase 1 |
| Completed | A Phase I Study of Fluzoparib in Patient With Advanced Solid Malignancies NCT02575651 | Jiangsu HengRui Medicine Co., Ltd. | Phase 1 |
| Completed | Japanese Phase I Study of AZD2014 in Advanced Solid Malignancies NCT02398747 | AstraZeneca | Phase 1 |
| Completed | Phase I, Dose Study to Look at the Safety and Pharmacokinetics of AZD8835 in Patients With Advanced Solid Tumo NCT02260661 | AstraZeneca | Phase 1 |
| Terminated | A Phase I Dose Escalation Study of Erlotinib in Combination With Theophylline NCT02080078 | AHS Cancer Control Alberta | Phase 1 |
| Completed | Phase1 Study of Gemcitabine HCl Oral Formulation(D07001-F4) in Patients With Advanced Solid Malignancies and M NCT01800630 | InnoPharmax Inc. | Phase 1 |
| Completed | Investigate the Safety and Tolerability of Olaparib Tablet in Japanese Patients With Advanced Solid Malignanci NCT01813474 | AstraZeneca | Phase 1 |
| Completed | Global Phase1 Study to Assess the Safety and Tolerability of AZD1208 in Advanced Solid Tumors and Malignant Ly NCT01588548 | AstraZeneca | Phase 1 |
| Completed | Investigate the Safety and Tolerability of AZD6244 Monotherapy or + Docetaxel in Japanese Patients With Advanc NCT01605916 | AstraZeneca | Phase 1 |
| Completed | Dose-escalation Study to Assess Safety, Tolerability and Pharmacokinetics of MEDI-573 in Japanese Subjects NCT01340040 | AstraZeneca | Phase 1 |
| Completed | Clinical Trial to Determine the MTD of HM781-36B in Patients With Advanced Solid Tumors NCT01455584 | Hanmi Pharmaceutical Company Limited | Phase 1 |
| Completed | Dose Escalation Study of MLN0128 in Combination With Paclitaxel, With/Without Trastuzumab, in Subjects With Ad NCT01351350 | Millennium Pharmaceuticals, Inc. | Phase 1 |
| Completed | Study to Assess Safety and Tolerability of AZD4547 in Japanese Patient NCT01213160 | AstraZeneca | Phase 1 |
| Terminated | A Phase I Study of AZD1480 in Patients With Advanced Solid Malignancies and Advanced Hepatocellular Carcinoma NCT01219543 | AstraZeneca | Phase 1 |
| Completed | A Trial to Determine the Maximum Tolerated Dose and Evaluate the Safety and Pharmacokinetics of Docetaxel-PNP, NCT01103791 | Samyang Biopharmaceuticals Corporation | Phase 1 |
| Completed | A Study of MEDI-575 in Patients With Advanced Solid Malignancies NCT01102400 | AstraZeneca | Phase 1 |
| Completed | Dose Escalation Study of MLN0128 in Participants With Advanced Malignancies NCT01058707 | Millennium Pharmaceuticals, Inc. | Phase 1 |
| Completed | Study to Assess the Safety, Tolerability, Pharmacokinetics (PK) and Preliminary Efficacy of AZD2014 NCT01026402 | AstraZeneca | Phase 1 |
| Terminated | Study is Designed to Assess the Safety and Tolerability of AZD4547 at Increasing Doses in Patients With Advanc NCT00979134 | AstraZeneca | Phase 1 |
| Completed | 10mg ZD4054 (Zibotentan) PK Study in Male, Elderly Chinese Patients With Advanced Solid Malignancies NCT00997945 | AstraZeneca | Phase 1 |
| Completed | A Study to Determine the Pharmacokinetics of Cediranib in Chinese Patients With Advanced Solid Malignancies NCT00981721 | AstraZeneca | Phase 1 |
| Completed | Study to Assess the Safety and Tolerability of the Tor Kinase Inhibitor AZD8055 NCT00973076 | AstraZeneca | Phase 1 |
| Terminated | Safety and Tolerability Study of AZD7762 in Combination With Gemcitabine NCT00937664 | AstraZeneca | Phase 1 |
| Completed | A Multiple-Ascending-Dose Study of the Safety and Tolerability of REGN421(SAR153192) in Patients With Advanced NCT00871559 | Regeneron Pharmaceuticals | Phase 1 |
| Completed | A Study of HSP990 Administered by Mouth in Adult Patients With Advanced Solid Tumors NCT00879905 | Novartis Pharmaceuticals | Phase 1 |
| Unknown | Analysis of Pharmacodynamic Changes With AUY922A, an HSP90 Inhibitor NCT01024283 | Royal Marsden NHS Foundation Trust | — |
| Terminated | Phase I, Open-label, Dose-escalation, Safety and PK Study of AZD6918 NCT00733031 | AstraZeneca | Phase 1 |
| Completed | Clinical Trial to Evaluate Safety and Tolerability of OratecanTM in Patients With Advanced Solid Malignancies NCT00979563 | Hanmi Pharmaceutical Company Limited | Phase 1 |
| Completed | Clinical Trial to Evaluate Safety and Tolerability of OratecanTM in Patients With Advanced Solid Malignancies NCT00986843 | Hanmi Pharmaceutical Company Limited | Phase 1 |
| Completed | Absorption, Distribution, Metabolism and Excretion (ADME) Study of TKI258 in Patients With Advanced Solid Mali NCT00669097 | Novartis Pharmaceuticals | Phase 1 |
| Completed | Study of AZD8931 in Patients With Advanced Solid Malignancies NCT00637039 | AstraZeneca | Phase 1 |
| Completed | Open Label, Dose Escalation Phase I Study of AZD2281 NCT00572364 | AstraZeneca | Phase 1 |
| Terminated | A Study of BMS-663513 Administered in Combination With Chemotherapy to Subjects With Advanced Solid Malignanci NCT00351325 | Bristol-Myers Squibb | Phase 1 |
| Terminated | Phase I Single Ascending Dose/Multiple Ascending Dose in Patients Treated With AZD7762 and Irinotecan NCT00473616 | AstraZeneca | Phase 1 |
| Completed | Phase I Study of GW572016 With Topotecan to Treat Advanced Solid Malignancies NCT00295243 | Mayo Clinic | Phase 1 |